Cheong-Weon Cho

Dr. Cheong-Weon Cho

Chungnam National University
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2017 in Journal of Pharmaceutical Investigation
Verified
Journal Article
Closed access
PDF file
GSGi-Ho Son
Gi-Ho Son
BLBeom-Jin Lee
Beom-Jin Lee
Cheong-Weon ChoCheong-Weon Cho
Cheong-Weon Cho

1 August 2017 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
JBJong-Suep Baek
Jong-Suep Baek
Cheong-Weon ChoCheong-Weon Cho
Cheong-Weon Cho

1 August 2008 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
JOJae-Ho Oh
Jae-Ho Oh
HPHyoun-Hyang Park
Hyoun-Hyang Park
KDKi-Young Do
Ki-Young Do
MHManhee Han
Manhee Han
DHDong-Hun Hyun
Dong-Hun Hyun
Cheong-Weon ChoCheong-Weon Cho
Cheong-Weon Cho

13 March 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
JBJong-Suep Baek
Jong-Suep Baek
Cheong-Weon ChoCheong-Weon Cho
Cheong-Weon Cho
A multifunctional lipid nanoparticle for co-delivery of paclitaxel and curcumin for targeted delivery and enhanced cytotoxicity in multidrug resistant breast cancer cells

1 January 2015 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
JBJong-Suep Baek
Jong-Suep Baek
Cheong-Weon ChoCheong-Weon Cho
Cheong-Weon Cho

11 June 2019 in Cancers
Verified
Journal Article
Open access
PDF file
KBKiHyun Bang
KiHyun Bang
YNYoung-Guk Na
Young-Guk Na
HHHyun Wook Huh
Hyun Wook Huh
Sung-Joo HwangSung-Joo Hwang
Sung-Joo Hwang
Min-Soo KimMin-Soo Kim
Min-Soo Kim
Cheong-Weon ChoCheong-Weon Cho
Cheong-Weon Cho
Strategies for the development of anticancer drug delivery systems have undergone a dramatic transformation in the last few decades. Lipid-based drug delivery systems, such as a nanostructured lipid carrier (NLC), are one of the systems emerging to improve the outcomes of tumor treatments. However, NLC can act as an intruder and cause an immune response. To overcome this limitation, biomimicry technology was introduced to decorate the surface of the nanoparticles with various cell membrane proteins. Here, we designed paclitaxel (PT)-loaded nanostructured lipid carrier (PT-NLC) with platelet (PLT) membrane protein because PLT is involved with angiogenesis and interaction of circulating tumor cells. After PLT was isolated from blood using the gravity-gradient method and it was used for coating PT-NLC. Spherical PT-NLC and platelet membrane coated PT-NLC (P-PT-NLC) were successfully fabricated with high encapsulation efficiency (EE) (99.98%) and small particle size (less than 200 nm). The successful coating of PT-NLC with a PLT membrane was confirmed by the identification of CD41 based on transmission electron microscopy (TEM), western blot assay and enzyme-linked immunosorbent assay (ELISA) data. Moreover, the stronger affinity of P-PT-NLC than that of PT-NLC toward tumor cells was observed. In vitro cell study, the PLT coated nanoparticles successfully displayed the anti-tumor effect to SK-OV-3 cells. In summary, the biomimicry carrier system P-PT-NLC has an affinity and targeting ability for tumor cells.